|
Vernalis is to merge with British Biotech to create a combined biotechnology group with a market capitalisation of £90m, and the staffing levels will be cut from 204 to 130. 04-Jul-2003 British Biotech is forming an alliance with MerLion Pharmaceuticals of Singapore to develop anti-bacterial treatments from natural products. 15-May-2003 British Biotech is to merge with RiboTargets, creating a combined biotechnology group with a market value of £52m. 24-Mar-2003 British Biotech is seeking acquisitions and research collaborations in Europe and North America in order to expand its portfolio of drugs. 08-Jul-2002 British Biotech is to transfer 59 research staff and two office facilities to OSI for £8.7m, in order to reduce annual costs in its drug development business by £6m. 08-Aug-2001 British Biotech is to sell its Oxford headquarters in a £11m sale and leaseback deal, as part of a strategy to sell non-core assets to fund drug development. 26-Mar-2001 British Biotech is forming an alliance with Serono of Switzerland to develop new treatments for inflammatory diseases. 18-Oct-2000 British Biotech is planning to focus on the development of antibiotics, in order to reinvent itself following the disappointing results from its marimastat cancer drug. 06-Jul-2000 British Biotech is to cut at least 90 jobs from its medical research and administration functions, in order to focus more resources on drug development. 12-Jun-2000 British Biotech is considering plans to hire out its surplus laboratories to other research companies in order to raise up to £1m a year. 19-Nov-1999 British Biotech is to shed 66 jobs at its head office and research departments, reducing the total headcount to 235. 01-Oct-1999 British Biotech is forming an alliance with Schering-Plough in which the US company will help finance and develop British Biotech's cancer inhibitors. 08-Sep-1999 British Biotech has abandoned further development of its Zacutex treatment for pancreatitis, one of its two key drug developments, due to poor clinical trial results. 26-Mar-1999 British Biotech has dropped plans to build up an international sales operation and will instead use a major pharmaceuticals group to sell its marimastat cancer treatment. 14-Nov-1998 British Biotech has announced it will have to wait at least another year until it can launch its Zacutex treatment for acute pancreatitis, as it has to complete phase III trials before the European Medicines Evaluation Authority will consider it. 06-Feb-1998 British Biotech has cancelled development of its BB-2983 arthritis drug, a project it was working on with Glaxo Wellcome. 04-Oct-1997 British Biotech has announced successful early trials for its new cancer drug, marimastat, when used with existing treatments. 24-Sep-1997 Oxagen is being created as the UK's first genomics company by former British Biotech executives, in order to study the links between genes and disease. 22-Sep-1997 British Biotech is delaying US clinical trials on Zacutex, its pancreas disease drug, as results so far have not been as expected. 10-Jul-1997 British Biotech is setting up sales subsidiaries in France, Germany, Spain, Italy and the Nordic region in preparation for the launch of its acute pancreatitis drug Zacutex. 13-May-1997 British Biotech is investing in a research programme being carried out by SynPhar Laboratories of Canada in order to develop potential drugs known as cysteine proteinase inhibitors. 29-Apr-1997 British Biotech has requested European approval for Zacutex, a pancreas disease drug which represents its first product. 06-Mar-1997 British Biotech has begun human trials of BB-2983, its arthritis drug, in association with Glaxo Wellcome. 29-Nov-1996 British Biotech is preparing to launch its first product in 1998 - lexipafant, a treatment for acute pancreatic disease. 28-Nov-1996 British Biotech is to receive up to £45m from Tanabe Seiyaku for the development and marketing of marimastat, its oral anti-cancer drug, in Japan. 15-Nov-1996 British Biotech has seen only about half its shareholders take up its £143m rights issue, in a further disappointment for the UK biotechnology sector. 18-Jul-1996 British Biotech is planning a £143m rights issue to fund its development into a major international pharmaceutical group. 27-Jun-1996 British Biotech has announced promising test results for marimastat, its cancer drug. 01-Dec-1995 Glaxo Wellcome has made a licensing deal with British Biotech, in which it will develop the drug BB2983 as an oral arthritis treatment. 28-Sep-1995 British Biotech has successfully trialled its acute pancreatic treatment, lexipafant. 15-Sep-1995
|